ADC Process & Analytical Development
ADC development requires coordinated optimization of conjugation chemistry, reaction conditions, purification processes, and analytical methods to establish a reproducible process and well-defined product quality profile. Protheragen provides integrated process and analytical development support for ADC programs, covering conjugation feasibility, process optimization, purification development, process characterization, and analytical evaluation from early development through manufacturing readiness.
Overview of ADC Process & Analytical Development
Antibody-drug conjugates (ADCs) combine an antibody with a linker and a highly potent payload, creating a molecular system with greater structural and process complexity than conventional antibody products. The conjugation strategy, reaction conditions, purification approach, and handling conditions can directly influence critical quality attributes such as drug-to-antibody ratio (DAR), DAR distribution, aggregation, free drug, unconjugated antibody, and other product- and process-related impurities.
Process and analytical development requires an integrated approach that connects conjugation chemistry with product characterization and process control. Depending on the ADC design, development may involve conventional cysteine- or lysine-based conjugation as well as site-specific approaches. Site-specific conjugation can provide greater control over DAR and product homogeneity, while requiring process strategies that address conjugation efficiency, scalability, and consistency.
Fig.1 Scheme of site-specific conjugation techniques and interchain cysteine conjugation process. (Fan Q, et al., 2025)
Our Services
Conjugation Process Development
Conjugation processes are developed according to the molecular design and selected conjugation chemistry. Development activities may include reaction condition screening, reagent ratio optimization, reaction time and temperature evaluation, and assessment of conjugation efficiency and product quality.
Both conventional and site-specific conjugation strategies can be considered according to the characteristics and development requirements of the ADC molecule.
Purification Process Development
Purification development focuses on removing unconjugated antibody, free linker-payload, residual reagents, aggregates, and other process- or product-related impurities while maintaining ADC recovery and product integrity.
Chromatographic and complementary purification approaches can be evaluated to establish an effective purification strategy suitable for subsequent scale-up.
Process Optimization & Characterization
Process parameters are systematically evaluated to understand their influence on ADC quality attributes and process performance. Development studies may include parameter screening, optimization, robustness assessment, and characterization of the conjugation and purification steps.
This approach helps establish a stronger understanding of the relationship between process conditions and critical quality attributes, supporting the development of a more reproducible and scalable manufacturing process.
Analytical Method Development
Analytical methods are developed to monitor key ADC attributes throughout process development. Depending on the molecule and development stage, analytical evaluation may include DAR and drug-load distribution, aggregation and size variants, purity, molecular integrity, residual components, and other product-related attributes.
Chromatographic approaches such as hydrophobic interaction chromatography (HIC), reversed-phase liquid chromatography (RPLC), and size-exclusion chromatography (SEC) are commonly used for ADC characterization, including assessment of drug loading, DAR, impurities, and size variants.
Analytical Characterization & Process Monitoring
Analytical data are integrated with process development to evaluate the impact of process conditions on ADC quality. Characterization may address molecular mass, conjugation profile, DAR distribution, aggregation, purity, structural integrity, and other relevant quality attributes.
Advanced mass spectrometry-based approaches can provide additional information on molecular integrity, drug distribution, conjugation sites, and product modifications, supporting deeper understanding of ADC structure and process-related variability.
Analytical Evaluation of Key ADC Attributes
ADC molecules require analytical strategies that address both conventional antibody attributes and ADC-specific quality characteristics.
| Quality Attribute |
Development Focus |
Typical Analytical Approaches |
| Drug-to-Antibody Ratio (DAR) |
Average drug loading and DAR distribution |
HIC, MS |
| Aggregation & Size Variants |
High-molecular-weight species and fragmentation |
SEC, CE-SDS |
| Purity |
Product-related and process-related impurities |
HPLC, CE, LC-MS |
| Molecular Integrity |
Intact mass and molecular composition |
Mass spectrometry |
| Conjugation Profile |
Conjugation sites and drug distribution |
LC-MS, peptide mapping |
| Free Drug / Linker-Payload |
Residual unconjugated components |
LC-MS, HPLC |
| Charge Variants |
Charge heterogeneity associated with the ADC |
IEX, icIEF |
| Stability-Related Changes |
Degradation and structural changes |
SEC, HIC, LC-MS and complementary methods |
The analytical strategy can be adapted according to the ADC molecule, conjugation chemistry, development stage, and intended manufacturing process. DAR and drug-load distribution are particularly important because changes in drug loading can affect potency, stability, pharmacokinetics, and toxicity.
Integrated Process & Analytical Development
Process development and analytical development are closely connected throughout ADC development. Analytical data generated during conjugation and purification studies can be used to identify process-related variability, evaluate critical process parameters, and guide optimization decisions.
A coordinated strategy may include:
- Conjugation Evaluation — Assess conjugation efficiency, reaction performance, and initial product quality.
- Purification Development — Evaluate impurity clearance, product recovery, and preservation of ADC integrity.
- CQA Assessment — Identify and monitor ADC-specific quality attributes such as DAR, drug-load distribution, aggregation, and free drug.
- Process Characterization — Investigate the relationship between process parameters and product quality.
- Method Development — Establish fit-for-purpose analytical methods for development and process monitoring.
- Process Readiness — Generate process knowledge and analytical data to support scale-up and technology transfer.
This integrated approach helps reduce the disconnect between process development and analytical characterization, allowing process decisions to be evaluated against measurable product quality attributes.
Development Support Across ADC Programs
Process and analytical development strategies can be adapted to different ADC development scenarios, including:
Early-Stage ADC Feasibility
Early development programs can benefit from rapid evaluation of conjugation feasibility, preliminary process conditions, and initial product quality to support candidate selection and development planning.
Process Optimization for Existing ADC Candidates
For established ADC candidates, targeted optimization can focus on improving conjugation efficiency, purification performance, product recovery, or consistency while maintaining the desired quality profile.
Site-Specific ADC Development
Site-specific conjugation approaches require coordinated evaluation of conjugation efficiency, DAR control, product homogeneity, and process robustness. Such strategies can provide greater control over drug loading and conjugation profiles but may introduce specific process-development requirements.
Scale-Up and Manufacturing Readiness
Process knowledge generated during development can be used to support scale-up, process characterization, technology transfer, and preparation of manufacturing-ready processes.
Why Choose Protheragen
- Integrated Process and Analytical Capabilities
Process development and analytical evaluation are coordinated within the same development strategy, allowing product quality to be assessed alongside process performance.
- ADC-Focused Development Strategy
Development activities are designed around the specific characteristics of ADC molecules, including conjugation chemistry, DAR distribution, purification behavior, and product heterogeneity.
- Flexible Conjugation Approaches
Both conventional and site-specific conjugation strategies can be considered according to molecule characteristics and project requirements.
- Data-Driven Process Optimization
Analytical results are used to evaluate the relationship between process parameters and product quality, supporting more informed process optimization and characterization.
- Development-to-Manufacturing Continuity
Process knowledge, analytical methods, and characterization data generated during development can provide a foundation for subsequent scale-up, technology transfer, and manufacturing activities.
Effective ADC process development requires a clear understanding of how conjugation and purification conditions influence product quality and process performance. By integrating process development with analytical evaluation and characterization, Protheragen supports the establishment of robust, reproducible ADC processes and provides development data to facilitate subsequent scale-up and manufacturing. Contact us to discuss your molecule, development stage, and project requirements. Our team can help define an appropriate process and analytical development strategy based on your specific ADC program.
Reference
- Fan Q, et al. "review of conjugation technologies for antibody drug conjugates" Antib Ther. 2025; 8(2):157-170
